Evidence map›Paper›PMID 24652992›Full record

Trial reportBlood2014

Objective responses in relapsed T-cell lymphomas with single-agent brentuximab vedotin.

Steven M Horwitz, Ranjana H Advani, Nancy L Bartlett, Eric D Jacobsen, Jeff P Sharman, Owen A O'Connor, Tanya Siddiqi, Dana A Kennedy, Yasuhiro Oki

3 registry-linked trialsOpen access · bronzeAbstract readClinical Trial, Phase IIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Blood, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 170 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
170citing papers in PubMed, 4 pooled it
24.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT01421667 phase2completednot on this map

A Phase 2 Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)

TypeinterventionalSponsorSeagen Inc.Ran2011 to 2015Enrolled176ConditionsLymphoma, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Non-Hodgkin, Lymphoma, T-CellArmsbrentuximab vedotin, rituximab
NCT03964480 recruitingnot on this mapstarted 2018, after this paper: background citation

Prospective Observational International Registry of Patients With Newly Diagnosed Peripheral T Cell Lymphoma.

Typeobservational_patient_registrySponsorAssociazione Angela Serra per la ricerca sul cancroRan2018 to 2025Enrolled1,000ConditionsPeripheral T-Cell Lymphoma
NCT05313243 phase2recruitingnot on this mapstarted 2023, after this paper: background citation

Phase 2 Study of Pembrolizumab and Brentuximab Vedotin in Subjects With Relapsed/Refractory CD30 Positive T-cell Lymphoma

TypeinterventionalSponsorYale UniversityRan2023 to 2028Enrolled32ConditionsT-Cell LymphomaArmsBrentuximab vedotin, Pembrolizumab
3 · Its place in the literature

Who cites it

170 citing papers in PubMed, 4 syntheses or guidelines pooled it, 349 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. A Phase II Study of Acimtamig (AFM13) in Patients with CD30-Positive, Relapsed, or Refractory Peripheral T-cell Lymphomas.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025
    Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Trial
  16. Trial
  17. Trial
  18. Trial
  19. Trial
  20. Trial

110 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 9 institutions in 1 country.

Steven M HorwitzDepartment of Medicine, Lymphoma Service, Memorial Sloan-Kettering Cancer Center, New York, NY;
Ranjana H AdvaniDepartment of Medicine, Oncology Division, Stanford University Medical Center, Stanford, CA;
Nancy L BartlettDepartment of Internal Medicine, Division of Oncology, Washington University School of Medicine, St. Louis, MO;
Eric D JacobsenDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA;
Jeff P SharmanUS Oncology Research, Willamette Valley Cancer Institute and Research Center, Eugene, OR;
Owen A O'ConnorCenter for Lymphoid Malignancies, Department of Medicine, Columbia University Medical Center/New York Presbyterian Hospital, New York, NY;
Tanya SiddiqiDepartment of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA;
Dana A KennedySeattle Genetics, Inc., Bothell, WA; and.
Yasuhiro OkiDepartment of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, TX.
City Of Hope National Medical Center · USDana-Farber Cancer Institute · USMemorial Sloan Kettering Cancer Center · USNewYork–Presbyterian Hospital · USSeagen (United States) · USStanford University · USThe University of Texas MD Anderson Cancer Center · USWashington University in St. Louis · USWillamette Valley Cancer Institute and Research Center · US

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
NCI NIH HHS P30 CA016672
6 · The paper itself

Abstract

This phase 2, open-label, multicenter study evaluated the efficacy and safety of brentuximab vedotin, a CD30-directed antibody-drug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas. The primary end point was objective response rate (ORR). Key secondary end points included safety, correlation of CD30 expression with response, response duration, and progression-free survival (PFS). Brentuximab vedotin 1.8 mg/kg was administered every 3 weeks until progression or unacceptable toxicity. This planned subset analysis included patients with peripheral T-cell lymphomas (PTCLs; n = 35), specifically angioimmunoblastic T-cell lymphoma (AITL; n = 13) and PTCL not otherwise specified (n = 22). Median age was 64 years; 63% were refractory to most recent therapy. Of 34 evaluable patients, ORR was 41% (8 complete remissions [CRs], 6 partial remissions [PRs]), and ORR was 54% in AITL (5 CRs, 2 PRs) with median PFS of 6.7 months thus far. No correlation between CD30 expression per central review and response was observed. Safety data were consistent with the known profile of brentuximab vedotin, and included at least grade 3 events of neutropenia (14%), peripheral sensory neuropathy, and hyperkalemia (9% each). In summary, brentuximab vedotin showed antitumor activity in patients with relapsed PTCL particularly AITL. This trial was registered at www.clinicaltrials.gov as #NCT01421667.

Indexed as

AdultAgedAged, 80 and overBrentuximab VedotinFemaleHumansImmunoconjugatesKi-1 AntigenLymphoma, T-CellMaleMiddle AgedNeoplasm Recurrence, LocalBrentuximab VedotinImmunoconjugatesKi-1 Antigen

Identifiers

PMID24652992
PMCPMC4425442
OpenAlexW2032713012

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.